For the January 2014 webinar, Amanda Bistran-Hall presented on General Best Practices, Karen Lane gave us an update on our study drug Alteplase, and Sam Nekoovaght-Tak presented the World Cup Semi-Annual Awards.
Neurocritical Care Society Podcast on MISTIE IIIFor the November 2019 episode of the Neurocritical Care Society Podcast Series, Dr. Fawaz Al-Mufti was joined by Drs. Daniel Hanley and Issam Awad to discuss the results of the MISTIE III trial. Read More
Dan Hanley Named Deputy Director of Johns Hopkins ICTRDr. Daniel Hanley, director of the BIOS Division, has been named the Deputy Director for Support and Innovation in Multicenter Trials at the Johns Hopkins Institute for Clinical and Translational Research. Read More
MISTIE III: ‘A Big Step in the Right Direction’The Journal of NeuroInterventional Surgery reports that though the MISTIE III trial did not reach its primary endpoint of improved functional outcome at one year, it did generate a wealth of high-quality data that provide invaluable insight into this devastating disease. Read More
Surgical performance determines functional outcome benefit in the MISTIE procedure.
Awad IA, Polster SP, Carrión-Penagos J, et al. Neurosurgery. 2019;84(6):1157-68.
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage
evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.
Hanley DF, Thompson RE, Rosenblum M, et al. Lancet. 2019;393(10175):1021-32.
Enhancing the informed consent process using shared decision making and consent refusal data from the
CLEAR III trial.
Porter AL, Ebot J, Lane K, et al. Neurocritical Care. 2019 September 30.
Intensive blood pressure reduction and perihematomal edema expansion in deep intracerebral
Leasure AC, Qureshi AI, Murthy SB, et al. Stroke. 2019;50(8):2016-22.